A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.
A practical guide to the follow-up plan after a longevity assessment: clinical ownership, abnormal findings, referrals, retesting, records, costs, and red flags.
A buyer scorecard for separating completed tests, biomarker changes, functional progress, patient-important outcomes, safety, and unresolved follow-up.
A large Nature Medicine study inferred cell-type aging from plasma proteins. The model predicted risk at population level, but it is not a diagnosis or validated clinic treatment engine.
A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.
A 2026 buyer guide to AI diagnostics in longevity clinics: real use cases, red flags, physician oversight, FDA caveats, and questions before you pay.
A patient-safety guide to longevity clinic governance: medical accountability, evidence labels, diagnostics, AI, biomarkers, records, adverse events, and conflicts.
This weekly WLC intelligence digest covers serious clinic standards, AI diagnostics, GLP-1 programs, full-body MRI, biological-age testing, and peptides.
A clear 2026 guide to what longevity clinics do, what they cost, which tests matter, red flags to avoid, and how to compare clinics safely.
